Scarica l'app Stockscreener
13.21
6.25%
-0.88
Pre-mercato:
13.21
Panoramica
Notizia
Cronologia dei prezzi
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$14.09
Aprire:
$14.27
Volume 24 ore:
99,845
Relative Volume:
0.71
Capitalizzazione di mercato:
$221.70M
Reddito:
$6.67M
Utile/perdita netta:
$-47.55M
Rapporto P/E:
-8.8067
EPS:
-1.5
Flusso di cassa netto:
$-17.44M
1 W Prestazione:
+0.30%
1M Prestazione:
+1.46%
6M Prestazione:
+2,484%
1 anno Prestazione:
+2,484%
Intervallo 1D:
$12.97
$14.27
Intervallo di 1 settimana:
$12.97
$15.57
Portata 52W:
$9.81
$21.40
Crescent Biopharma Inc Stock (CBIO) Company Profile
Nome
Crescent Biopharma Inc
Settore
Industria
Telefono
617-430-5595
Indirizzo
300 FIFTH AVENUE, WALTHAM, CA
Confronta CBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
13.21 | 236.47M | 6.67M | -47.55M | -17.44M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-25 | Iniziato | Jefferies | Buy |
| 2025-08-11 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-14 | Iniziato | Wedbush | Outperform |
| 2025-06-25 | Iniziato | Stifel | Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-11 | Iniziato | Noble Capital Markets | Outperform |
| 2024-07-26 | Downgrade | TD Cowen | Buy → Hold |
| 2023-12-22 | Iniziato | CapitalOne | Overweight |
| 2021-11-12 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-04-29 | Ripresa | Stephens | Overweight |
| 2021-02-10 | Iniziato | Piper Sandler | Overweight |
| 2020-05-21 | Iniziato | Raymond James | Outperform |
| 2019-11-14 | Iniziato | ROTH Capital | Buy |
| 2019-08-05 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-05 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | Downgrade | SunTrust | Buy → Hold |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-01-04 | Iniziato | Oppenheimer | Outperform |
| 2018-12-18 | Iniziato | H.C. Wainwright | Buy |
| 2018-02-12 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Reiterato | Chardan Capital Markets | Buy |
| 2017-12-08 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Iniziato | Chardan Capital Markets | Buy |
| 2017-06-06 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-07-26 | Iniziato | SunTrust | Buy |
| 2016-06-30 | Iniziato | Rodman & Renshaw | Buy |
| 2015-03-17 | Reiterato | Stifel | Buy |
Mostra tutto
Crescent Biopharma Inc Borsa (CBIO) Ultime notizie
Huge insider buying in MGM and Salesforce - MSN
Frazier Life Sciences Management L.P. Takes Position in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
CBIO Insider Trading - Quiver Quantitative
GlycoMimetics executives to depart amid merger plans - MSN
BVF Inc. IL Makes New Investment in Crescent Biopharma, Inc. $CBIO - MarketBeat
Braidwell LP Invests $4.22 Million in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma, Inc. (CBIO) Stock News & Articles - 24/7 Wall St.
Crescent Biopharma (NASDAQ:CBIO) Director Fairmount Funds Management Llc Purchases 1,360,000 Shares of Stock - Defense World
Crescent, Kelun in two-way deal, including PD-1/VEGF bispecific - BioWorld MedTech
Fairmount Funds Management Llc Purchases 1,360,000 Shares of Crescent Biopharma (NASDAQ:CBIO) Stock - MarketBeat
Shareholder Fairmount Funds Management LLC Buys 1,360,000 ($18.2M) Of Crescent Biopharma Inc [CBIO] - TradingView — Track All Markets
Kelun-Biotech and Crescent Biopharma forge strategic oncology partnership - Indian Pharma Post
Affinity Asset Advisors LLC Makes New $4.52 Million Investment in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
China's Kelun-Biotech licenses cancer treatment to Crescent Biopharma - Reuters
Crescent Biopharma (NASDAQ:CBIO) Lowered to “Sell” Rating by Wall Street Zen - Defense World
Crescent Biopharma partners with Kelun-Biotech in oncology - BioWorld MedTech
Crescent and Kelun-Biotech swap cancer asset rights in double deal - Yahoo Finance
Check Out Crescent Biopharma Inc (CBIO)’s Trade Data Rather Than the Analysts’ Views - setenews.com
Asia Deal Watch: Kelun And Crescent Partner And Cross-License Cancer Candidates - Citeline News & Insights
China’s Kelun-Biotech licenses cancer treatment to Crescent Biopharma - 1470 & 100.3 WMBD
Crescent Biopharma stock price target raised by Stifel to $32 on Kelun deal - Investing.com South Africa
Stifel Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Raises Target Price to $32 - 富途牛牛
Sichuan Kelun-Biotech biopharmaceutical partners with Crescent Biopharma - marketscreener.com
What's Happening With Crescent Biopharma Stock Today? - Benzinga
Crescent and Kelun-Biotech get creative with two-way licensing deal - The Pharma Letter
The Deal That Sent Crescent Biopharma Shares Surging Over 40% Pre-Market Today - Asianet Newsable
Why Is Crescent Biopharma Stock (CBIO) Up Today? - TipRanks
Kelun-Biotech and Crescent Biopharma announce strategic partnership - marketscreener.com
Kelun-Biotech And Crescent Biopharma Announce Strategic Partnership - TradingView — Track All Markets
Crescent Biopharma partners with Kelun-Biotech, raises $185 million By Investing.com - Investing.com Nigeria
Crescent Biopharma stock soars after Kelun-Biotech partnership By Investing.com - Investing.com South Africa
Crescent Biopharma IncKelun-Biotech Eligib - 富途牛牛
Crescent, Kelun-Biotech Sign Oncology Deal; Crescent To Raise $185 Mln; Stock Up - Nasdaq
Kelun-Biotech and Crescent Biopharma form oncology partnership By Investing.com - Investing.com Australia
Kelun-Biotech and Crescent Biopharma… - digitalmore.co
Crescent Biopharma jumps after cancer drug partnership - TradingView — Track All Markets
Crescent Biopharma, Kelun-Biotech Biopharmaceutical Partner in Multimillion Dollar Deal to Develop Cancer Drugs - MarketScreener
Kelun-Biotech and Crescent Biopharma form oncology partnership - Investing.com
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics - PR Newswire
Is Crescent Biopharma Inc. (GKO0) stock a top hedge fund pickForecast Cut & Low Drawdown Momentum Trade Ideas - Newser
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors - GlobeNewswire
Kelun-Biotech and Crescent Biopharma Announce Strategic - GlobeNewswire
Jefferies Financial Group Inc. Buys New Stake in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Share Price Crosses Above 200-Day Moving AverageHere's Why - MarketBeat
Crescent Biopharma Inc (CBIO) - MSN
Crescent Biopharma (NASDAQ:CBIO) Share Price Crosses Above 200-Day Moving Average – Here’s Why - Defense World
Crescent Biopharma Inc Azioni (CBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):